The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

Cipla has been helping extend the reach of affordable life-saving HIV/AIDS medications since 2001. The company supplies antiretroviral (ARV) medicines to 64 countries by mostly participating in the ...

Shares of drugmaker Cipla Ltd. surged to the day's high, gaining as much as 4% after the company's December quarter results. The results were a beat across parameters.

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...

Drug major Cipla on Tuesday reported a 49% jump in its December quarter consolidated net profit at Rs 1,571 crore as compared to Rs 1,056 crore reported in the year-ago period. The profit after tax ...

Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin. The drugmaker posted a consolidated ...

Meanwhile, Vohra remained hopeful about rolling out Advair by the end of FY26 from Cipla’s New Jersey plant, as regulatory setbacks at the Pithampur facility necessitated a change in the launch ...

Pharmaceutical giant Cipla on January 28 reported a consolidated net profit of Rs 1,571 crore for the quarter ended on December 31. This marks a 49 percent rise from the Rs 1,056 crore net profit ...

Shares traded at ₹358.05 on the NSE, down 2.09%. Cipla Ltd recorded its consolidated net profit for the quarter ended December 2024 at ₹1,574.59 crore as against ₹1,068.41 crore in the ...

HYDERABAD/BENGALURU, Jan 28 (Reuters) - Cipla (CIPL.NS), opens new tab, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong ...

"Don't know on which basis they protested against" Arjun Ram Meghwal on Opposition's protest on JPC's report ...